Literature DB >> 31340063

Cancer mortality in kidney transplant recipients: An Australian and New Zealand population-based cohort study, 1980-2013.

Brenda M Rosales1, Nicole De La Mata1, Claire M Vajdic2, Patrick J Kelly1, Kate Wyburn3,4, Angela C Webster1,5.   

Abstract

Cancer burden is increasing in kidney transplant recipients, but differences in mortality compared to the general population remain unclear. We sought to compare cancer mortality in paediatric and adult kidney transplant recipients with the general population and describe any differences, by site, age and sex, country and over time. We included kidney transplant recipients from the Australian and New Zealand Dialysis and Transplantation Registry, 1980-2013. Date of death and underlying cause of death were ascertained by data-linkage and classified using ICD10AM codes. Indirect standardisation was used to estimate standardised mortality ratios (SMR). There were 5,284 deaths in 17,628 kidney transplant recipients over 175,084 person-years of observation, including 1,061 (20%) cancer deaths. Relative cancer mortality was higher than the general population for all-site (SMR 2.9, 95% CI 2.7-3.1) cancer and highest for nonmelanoma skin cancer (SMR 50.9, 95% CI 43.5-59.6) and lymphoma (SMR 42.2, 95% CI 35.3-50.5). Relative cancer mortality decreased with increasing age in men (p < 0.001) and women (p = 0.001) but never reached parity with the general population. Relative mortality did not change with age for skin and lip, or colorectal cancers (p-value >0.1). Only relative colorectal cancer mortality increased over time (p = 0.002). Our study shows cancer mortality in kidney transplant recipients was higher than expected in the general population. The magnitude of excess mortality varied by cancer site, age and sex. Further evidence is needed to identify whether this variation is due to differences at diagnosis or access and effectiveness of cancer treatments in this population.
© 2019 UICC.

Entities:  

Keywords:  cancer; end-stage kidney disease; kidney transplantation; mortality

Year:  2019        PMID: 31340063     DOI: 10.1002/ijc.32585

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  4 in total

1.  Dampened Inflammatory Signalling and Myeloid-Derived Suppressor-Like Cell Accumulation Reduces Circulating Monocytic HLA-DR Density and May Associate With Malignancy Risk in Long-Term Renal Transplant Recipients.

Authors:  Matthew J Bottomley; Paul N Harden; Kathryn J Wood; Joanna Hester; Fadi Issa
Journal:  Front Immunol       Date:  2022-07-01       Impact factor: 8.786

2.  Incidence of malignancy and related mortality after kidney transplantation: a nationwide, population-based cohort study in Korea.

Authors:  Seri Jeong; Ho Sup Lee; Seom Gim Kong; Da Jung Kim; Sangjin Lee; Min-Jeong Park; Wonkeun Song; John Hoon Rim; Hyung Jik Kim
Journal:  Sci Rep       Date:  2020-12-08       Impact factor: 4.379

3.  Kidney function and cancer risk: An analysis using creatinine and cystatin C in a cohort study.

Authors:  Jennifer S Lees; Frederick Ho; Solange Parra-Soto; Carlos Celis-Morales; Paul Welsh; Michael K Sullivan; Bhautesh D Jani; Naveed Sattar; Ninian N Lang; Jill P Pell; Angela C Webster; Patrick B Mark
Journal:  EClinicalMedicine       Date:  2021-07-26

4.  Association between Use of Hydrochlorothiazide and Risk of Keratinocyte Cancers in Kidney Transplant Recipients.

Authors:  Thibault Letellier; Florent Le Borgne; Clarisse Kerleau; Aurélie Gaultier; Jacques Dantal; Simon Ville
Journal:  Clin J Am Soc Nephrol       Date:  2020-11-10       Impact factor: 8.237

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.